Oruka Therapeutics, Inc. ORKA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.15M+5.4% | $27.64M-4.7% | $28.99M+20.3% | $24.09M+20.9% | $19.93M-73.5% | ||
| $7.29M+7.3% | $6.79M+32.7% | $5.12M+17.8% | $4.34M-15.9% | $5.16M-60.5% | ||
| $36.43M+5.8% | $34.43M+1.0% | $34.11M+20.0% | $28.43M+13.3% | $25.09M-71.5% | ||
| -$36.43M-5.8% | -$34.43M-1.0% | -$34.11M-20.0% | -$28.43M-13.3% | -$25.09M+71.5% | ||
| $4.61M-4.8% | $4.85M+26.6% | $3.83M-0.7% | $3.86M-5.7% | $4.09M-7.1% | ||
| -$31.82M-7.6% | -$29.58M+2.3% | -$30.28M-23.2% | -$24.57M-17.0% | -$21M+74.9% | ||
| -$36.39M-5.8% | -$34.4M-0.9% | -$34.09M-20.0% | -$28.41M-13.3% | -$25.07M+71.5% | ||
| -$36.43M-5.8% | -$34.43M-1.0% | -$34.11M-20.0% | -$28.43M-13.3% | -$25.09M+71.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Oruka Therapeutics, Inc. profitable?
- Oruka Therapeutics, Inc. is not currently profitable: it reported a net loss of $116.3M over the trailing twelve months.
- What is Oruka Therapeutics, Inc.'s earnings per share?
- Oruka Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-6.19.
- Where does Oruka Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Oruka Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.